Influenza-A-virus-vaccine-H1N1, adverse reactionsSensation-disorders, drug-inducedA 30-year-old woman developed lipoatrophy following vaccination with influenza A virus vaccine-H1N1 [Pandemrix]. In November 2009, the woman received an IM injection of AS03A adjuvanted influenza A virus vaccine-H1N1 [...
摘要: The article describes the case of a 75-year-old man who developed severe chronic obstructive pulmonary disease and dyspnoea 8 weeks after receiving a seasonal influenza virus vaccine and 2 weeks after receiving an influenza A virus vaccine H1N1....
These results indicated for the first time that a high-growth SC/PR8 reassortant H1N1 virus exhibits properties that are desirable to be a promising vaccine candidate for use in swine in the event of a pandemic H1N1 influenza. 展开 关键词: Influenza A virus H1N1 Swine Vaccine Reassortant virus...
Laboratory testing has found the H1N1 influenza A (swine flu) virus susceptible to the prescription antiviral drugs oseltamivir and zanamivir. Other antiviral agents (eg, amantadine, rimantadine) are not recommended because of recent resistance to other influenza strains documented over the past severa...
virus vaccine-H1N1. Influenza A virus vaccine-H1N1.Influenza A virus vaccine-H1N1.doi:10.1007/s40278-013-4294-0The article presents a case study of 31-year-old woman who developed influenza A virus vaccine-H1N1 toxicities.EBSCO_AspReactions Weekly...
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in... Virus-like particles (VLPs) can be rapidly developed from influenza virus genetic sequences in order to supply vaccine after the onset ...
Influenza A virus H1N1 vaccine - CEL-SCI Alternative Names: L.E.A.P.S. swine flu vaccine - CEL-SCI; LEAPS-H1N1; LEAPS-H1N1-DC Latest Information Update: 18 Jun 2018 Price : €55 * Buy Profile Note: Adis is an information provider. We do not sell or distribute actual drug...
Influenza virus vaccine/influenza A virus vaccine H1N1 An event is serious (FDA MedWatch definition) when the patient outcome is: death life-threatening hospitalisation disability congenital anomaly requires in... &NA; - 《Reactions Weekly》
Influenza A virus H1N1 vaccine is developed by Sanofi for the prevention of influenza A virus H1N1 subtype infections. Panenza® is a non-adjuvanted,
which can be simultaneously identified by MS-based approach with high sensitivity. Williams et al. presented a LC/MS/MS approach to quickly identify the HA subtypes in different influenza virus strains so as to improve the efficiency and effectiveness for vaccine preparations and productions[101]...